Spyre Therapeutics, Inc. $SYRE is Affinity Asset Advisors LLC’s 6th Largest Position

Affinity Asset Advisors LLC decreased its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 10.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,279,134 shares of the company’s stock after selling 153,457 shares during the period. Spyre Therapeutics accounts for 3.3% of Affinity Asset Advisors LLC’s portfolio, making the stock its 6th largest position. Affinity Asset Advisors LLC’s holdings in Spyre Therapeutics were worth $64,520,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of SYRE. Summit Securities Group LLC purchased a new position in shares of Spyre Therapeutics in the 1st quarter worth $28,000. KBC Group NV purchased a new stake in Spyre Therapeutics during the first quarter valued at about $69,000. Russell Investments Group Ltd. grew its position in Spyre Therapeutics by 2,881.7% during the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after acquiring an additional 4,092 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Spyre Therapeutics during the fourth quarter worth about $74,000. Finally, Tower Research Capital LLC TRC increased its stake in Spyre Therapeutics by 182.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after acquiring an additional 3,725 shares during the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Analyst Upgrades and Downgrades

SYRE has been the topic of a number of recent research reports. Robert W. Baird lifted their price target on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Jefferies Financial Group raised their target price on shares of Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Citigroup lifted their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Spyre Therapeutics from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Finally, Wells Fargo & Company raised their price objective on Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.42.

Insider Activity

In other Spyre Therapeutics news, CFO Scott L. Burrows sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $87.13, for a total value of $1,306,950.00. Following the sale, the chief financial officer owned 97,994 shares in the company, valued at approximately $8,538,217.22. This trade represents a 13.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sheldon Sloan sold 78,333 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $71.50, for a total value of $5,600,809.50. Following the completion of the sale, the insider owned 78,333 shares in the company, valued at approximately $5,600,809.50. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 282,500 shares of company stock worth $21,741,101 over the last ninety days. Insiders own 15.69% of the company’s stock.

Spyre Therapeutics Stock Performance

Shares of SYRE stock opened at $102.13 on Friday. The stock has a market capitalization of $8.98 billion, a price-to-earnings ratio of -49.10 and a beta of 3.02. Spyre Therapeutics, Inc. has a one year low of $14.51 and a one year high of $105.09. The company’s 50-day simple moving average is $85.42 and its 200-day simple moving average is $60.57.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.08). As a group, research analysts forecast that Spyre Therapeutics, Inc. will post -2.86 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.